CN107595853A - A kind of medical composition and its use for being used to treat hypertensive patients coronary heart disease - Google Patents
A kind of medical composition and its use for being used to treat hypertensive patients coronary heart disease Download PDFInfo
- Publication number
- CN107595853A CN107595853A CN201711011984.3A CN201711011984A CN107595853A CN 107595853 A CN107595853 A CN 107595853A CN 201711011984 A CN201711011984 A CN 201711011984A CN 107595853 A CN107595853 A CN 107595853A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- weight
- composition according
- tripami
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Abstract
The present invention relates to a kind of medical composition and its use for being used to treat hypertensive patients coronary heart disease, described pharmaceutical composition includes the composition of following parts by weight：10 20 parts of Ansai Qu, 10 20 parts of Hydrochioro, 14 28 parts of tripami, 5 15 parts of protected acidic agent, 5 15 parts of antioxidant, 25 55 parts of filler, 15 30 parts of adhesive, 10 35 parts of disintegrant, 2 10 parts of lubricant.The present invention combines Ansai Qu, Hydrochioro and tripami for treating hypertensive patients coronary heart disease, curative effect highly significant, shows Synergistic, the effect having complementary advantages, moreover it is possible to substantially reduce each side effects of pharmaceutical drugs.
Description
Technical field
The invention belongs to pharmaceutical technology field, and in particular to a kind of drug regimen for being used to treat hypertensive patients coronary heart disease
Thing and application thereof.
Background technology
With the development of society and the improvement of living condition, the incidence of disease of coronary heart disease is in rising trend, and hypertension is coronary disease
The important risk factor of disease, for the patient of coronary heart disease with hypertension, complex treatment is preferred plan, therefore develops and treat
Effect is high, the complex treatment of Small side effects this sick medicine has important practical significance.Treatment with western coronary heart disease is closed at present
And hypertension is to separate the disease for the treatment of two, various medication species, the increase of incidence of side effect be present, Long-term taking medicine is costly, suffers from
In place of the deficiencies of person's compliance difference.The Chinese medicine compound prescription of traditional Chinese medicine possesses multicomponent, Mutiple Targets, the advantage of multipath treatment disease,
One side's multiple-effect, it is convenient and safe, treat both principal and secondary aspect of disease, a kind of new thinking is provided for clinical treatment hypertensive patients coronary heart disease.
The content of the invention
The present invention is intended to provide a kind of toxic side effect that is used for is small, and it is safe, treat hypertensive patients coronary heart disease good effect
A kind of pharmaceutical composition.
The technical scheme that the present invention takes is as follows：
One aspect of the present invention provides a kind of pharmaceutical composition, includes the composition of following parts by weight：Ansai Qu 10-20
Part, Hydrochioro 10-20 parts, tripami 14-28 parts, protected acidic agent 5-15 parts, antioxidant 5-15 parts, filler 25-55 parts,
Adhesive 15-30 parts, disintegrant 10-35 parts, lubricant 2-10 parts.
Further, the composition of following parts by weight is included：20 parts of Ansai Qu, 16 parts of Hydrochioro, 16 parts of tripami,
10 parts of protected acidic agent, 10 parts of antioxidant, 40 parts of filler, 25 parts of adhesive, 20 parts of disintegrant, 8 parts of lubricant.
Further, the protected acidic agent is the one or more in citric acid, ascorbic acid, tartaric acid.
Further, the antioxidant is Tea Polyphenols, butylated hydroxy anisole, dibutyl hydroxy toluene, the tert-butyl group to benzene
One or more in diphenol.
Further, the filler is starch, lactose, mannitol, dextrin, the one or more of microcrystalline cellulose.
Further, described adhesive is starch slurry, hydroxypropyl cellulose, sodium carboxymethylcellulose, polyvinylpyrrolidine
Ketone, methylcellulose, the one or more of ethyl cellulose.
Further, the disintegrant is sodium carboxymethylcellulose, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, friendship
Join the one or more in polyvinylpyrrolidone.
Further, the lubricant is the one or more in superfine silica gel powder, Macrogol 6000, talcum powder.
Further, the formulation of described pharmaceutical composition is tablet.
A kind of application of pharmaceutical composition as described above in the medicine for preparing treatment hypertensive patients coronary heart disease.
Ansai Qu, Hydrochioro and tripami drug combination are used for the treatment of hypertensive patients coronary heart disease, and curative effect is very
Significantly, Synergistic, the effect having complementary advantages are shown, moreover it is possible to substantially reduce Ansai Qu, Hydrochioro and tripami folk prescription
The side effect of medication.
Embodiment
Embodiments of the present invention are described in detail below with reference to embodiment, and illustrated embodiment is served only for explaining this hair
It is bright, it is not intended to limit the scope of the present invention.
The experimental method of unreceipted actual conditions in the following example, generally according to normal condition, or according to manufacturer
Proposed condition.
Involved medicine or reagent are commercial goods in the embodiment of the present invention.
Embodiment 1
Formula composition：
The parts by weight of Ansai Qu 20
The parts by weight of Hydrochioro 16
The parts by weight of tripami 16
The parts by weight of citric acid 10
The parts by weight of butylated hydroxy anisole 10
The parts by weight of lactose 40
The parts by weight of hydroxypropyl cellulose 25
The parts by weight of sodium carboxymethyl starch 20
The parts by weight of superfine silica gel powder 8
Preparation method：
1) Ansai Qu, Hydrochioro and the tripami of recipe quantity are taken, adds citric acid, butylated hydroxy anisole, lactose
It is well mixed, it is standby.
2) fully mixed to 1) middle hydroxypropyl cellulose, PVPP, the sodium carboxymethyl starch of adding, cross 80
Mesh sieve, ethanol softwood, cross the granulation of 14 mesh sieves.
3) dry, whole grain, add tabletting after superfine silica gel powder mixes, produce.
Embodiment 2
Formula composition：
The parts by weight of Ansai Qu 20
The parts by weight of Hydrochioro 20
The parts by weight of tripami 28
The parts by weight of citric acid 15
The parts by weight of butylated hydroxy anisole 15
The parts by weight of lactose 55
The parts by weight of hydroxypropyl cellulose 30
The parts by weight of sodium carboxymethyl starch 35
The parts by weight of superfine silica gel powder 10
Preparation method：
1) Ansai Qu, Hydrochioro and the tripami of recipe quantity are taken, adds citric acid, butylated hydroxy anisole, lactose
It is well mixed, it is standby.
2) fully mixed to 1) middle hydroxypropyl cellulose, PVPP, the sodium carboxymethyl starch of adding, cross 80
Mesh sieve, ethanol softwood, cross the granulation of 14 mesh sieves.
3) dry, whole grain, add tabletting after superfine silica gel powder mixes, produce.
Embodiment 3
Formula composition：
The parts by weight of Ansai Qu 10
The parts by weight of Hydrochioro 10
The parts by weight of tripami 14
The parts by weight of citric acid 5
The parts by weight of butylated hydroxy anisole 5
The parts by weight of lactose 25
The parts by weight of hydroxypropyl cellulose 15
The parts by weight of sodium carboxymethyl starch 10
The parts by weight of superfine silica gel powder 2
Preparation method
1) Ansai Qu, Hydrochioro and the tripami of recipe quantity are taken, adds citric acid, butylated hydroxy anisole, lactose
It is well mixed, it is standby.
2) fully mixed to 1) middle hydroxypropyl cellulose, PVPP, the sodium carboxymethyl starch of adding, cross 80
Mesh sieve, ethanol softwood, cross the granulation of 14 mesh sieves.
3) dry, whole grain, add tabletting after superfine silica gel powder mixes, produce.
Comparative example 1
Formula composition：
The parts by weight of Ansai Qu 40
The parts by weight of citric acid 10
The parts by weight of butylated hydroxy anisole 10
The parts by weight of lactose 40
The parts by weight of hydroxypropyl cellulose 25
The parts by weight of sodium carboxymethyl starch 20
The parts by weight of superfine silica gel powder 8
Preparation method：
1) Ansai Qu of recipe quantity is taken, citric acid, butylated hydroxy anisole, lactose is added and is well mixed, it is standby.
2) fully mixed to 1) middle hydroxypropyl cellulose, PVPP, the sodium carboxymethyl starch of adding, cross 80
Mesh sieve, ethanol softwood, cross the granulation of 14 mesh sieves.
3) dry, whole grain, add tabletting after superfine silica gel powder mixes, produce.
Comparative example 2
Formula composition：
The parts by weight of Hydrochioro 32
The parts by weight of tripami 32
The parts by weight of citric acid 10
The parts by weight of butylated hydroxy anisole 10
The parts by weight of lactose 40
The parts by weight of hydroxypropyl cellulose 25
The parts by weight of sodium carboxymethyl starch 20
The parts by weight of superfine silica gel powder 8
Preparation method：
1) Hydrochioro, the tripami of recipe quantity are taken, citric acid, butylated hydroxy anisole, lactose is added and is well mixed, it is standby
With.
2) fully mixed to 1) middle hydroxypropyl cellulose, PVPP, the sodium carboxymethyl starch of adding, cross 80
Mesh sieve, ethanol softwood, cross the granulation of 14 mesh sieves.
3) dry, whole grain, add tabletting after superfine silica gel powder mixes, produce.
Experimental example
Choose hypertensive patients patients with coronary heart disease 150, the one full year of life of average age 55, be divided into 5 groups, every group of 30 people, its
In first group of pharmaceutical composition for taking embodiment 1, second group of pharmaceutical composition for taking embodiment 2, the 3rd group is taken implementation
The pharmaceutical composition of example 3, the 4th group of pharmaceutical composition for taking comparative example 1, the 5th group of pharmaceutical composition for taking comparative example 2.
Daily 1, two weeks are a course for the treatment of, continuously take two courses for the treatment of.Take pharmaceutical composition fore-and-aft survey patient's body of the present invention
Interior cholesterol level, low-density lipoprotein content and blood pressure, judge by following Evaluation principle：
It is effective：Pain is disappeared, and cholesterol level, serum low-density LP are decreased obviously, and diastolic pressure and systolic pressure drop
To normal range (NR)；
Take a turn for the better：Pain relief, cholesterol level, serum low-density LP are decreased obviously, and diastolic pressure or systolic pressure are down to
Normal range (NR)；
It is invalid：Pain does not mitigate, and cholesterol level, serum low-density LP are not apparent from declining, diastolic pressure and systolic pressure
It is not apparent from declining.
Count obvious effective rate, improvement rate and inefficiency, wherein obvious effective rate=effective number/total number of persons；Improvement rate=improvement people
Number/total number of persons；Inefficiency=invalid number/total number of persons, total number of persons is 30, and statistical result is as shown in table 1：
Table 1
In the embodiment of the present invention 1, the dosage of Ansai Qu, Hydrochioro and tripami is the relative medicine one in comparative example
Half dose, from the point of view of pharmacodynamic results (as shown in table 1), using the pharmaceutical composition of the present invention with being used using Ansai Qu folk prescription
Medicine or Hydrochioro are compared with tripami drug combination, and obvious effective rate and improvement rate significantly improve, and illustrate Ansai Qu and esodrix
Piperazine and tripami combination have synergistic function.
The foregoing is only presently preferred embodiments of the present invention, be not intended to limit the invention, it is all the present invention spirit and
Within principle, any modification, equivalent substitution and improvements made etc., it should be included in the scope of the protection.
Claims (10)
1. a kind of pharmaceutical composition, it is characterised in that include the composition of following parts by weight：Ansai Qu 10-20 parts, esodrix
Piperazine 10-20 parts, tripami 14-28 parts, protected acidic agent 5-15 parts, antioxidant 5-15 parts, filler 25-55 parts, adhesive 15-
30 parts, disintegrant 10-35 parts, lubricant 2-10 parts.
2. pharmaceutical composition according to claim 1, it is characterised in that include the composition of following parts by weight：Ansai is bent
20 parts, 16 parts of Hydrochioro, 16 parts of tripami, 10 parts of protected acidic agent, 10 parts of antioxidant, 40 parts of filler, adhesive 25
Part, 20 parts of disintegrant, 8 parts of lubricant.
3. pharmaceutical composition according to claim 1 or 2, it is characterised in that the protected acidic agent is citric acid, anti-bad
One or more in hematic acid, tartaric acid.
4. pharmaceutical composition according to claim 1 or 2, it is characterised in that the antioxidant is Tea Polyphenols, butylhydroxy
One or more in anisole, dibutyl hydroxy toluene, TBHQ.
5. pharmaceutical composition according to claim 1 or 2, it is characterised in that the filler is starch, lactose, sweet dew
Alcohol, dextrin, the one or more of microcrystalline cellulose.
6. pharmaceutical composition according to claim 1 or 2, it is characterised in that described adhesive is starch slurry, hydroxypropyl fibre
Tie up element, sodium carboxymethylcellulose, polyvinylpyrrolidone, methylcellulose, the one or more of ethyl cellulose.
7. pharmaceutical composition according to claim 1 or 2, it is characterised in that the disintegrant be sodium carboxymethylcellulose,
One or more in sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, PVPP.
8. pharmaceutical composition according to claim 1 or 2, it is characterised in that the lubricant is superfine silica gel powder, poly- second two
One or more in alcohol 6000, talcum powder.
9. pharmaceutical composition according to claim 1 or 2, it is characterised in that the formulation of described pharmaceutical composition is tablet.
10. a kind of pharmaceutical composition as described in claim any one of 1-9 is preparing the medicine for the treatment of hypertensive patients coronary heart disease
Application in thing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711011984.3A CN107595853A (en) | 2017-10-25 | 2017-10-25 | A kind of medical composition and its use for being used to treat hypertensive patients coronary heart disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711011984.3A CN107595853A (en) | 2017-10-25 | 2017-10-25 | A kind of medical composition and its use for being used to treat hypertensive patients coronary heart disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107595853A true CN107595853A (en) | 2018-01-19 |
Family
ID=61079845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711011984.3A Withdrawn CN107595853A (en) | 2017-10-25 | 2017-10-25 | A kind of medical composition and its use for being used to treat hypertensive patients coronary heart disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107595853A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1899268A (en) * | 2006-07-13 | 2007-01-24 | 北京国仁堂医药科技发展有限公司 | L-amlodipine besilate dripping pill and its preparing method |
| CN103068816A (en) * | 2010-06-16 | 2013-04-24 | 武田药品工业株式会社 | Crystal of amide compound |
| CN104490775A (en) * | 2014-12-20 | 2015-04-08 | 长沙佰顺生物科技有限公司 | Anacetrapib fat emulsion and preparation method thereof |
| CN105748469A (en) * | 2016-02-24 | 2016-07-13 | 长沙佰顺生物科技有限公司 | Anacetrapib and simvastatin medicine composition |
-
2017
- 2017-10-25 CN CN201711011984.3A patent/CN107595853A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1899268A (en) * | 2006-07-13 | 2007-01-24 | 北京国仁堂医药科技发展有限公司 | L-amlodipine besilate dripping pill and its preparing method |
| CN103068816A (en) * | 2010-06-16 | 2013-04-24 | 武田药品工业株式会社 | Crystal of amide compound |
| CN104490775A (en) * | 2014-12-20 | 2015-04-08 | 长沙佰顺生物科技有限公司 | Anacetrapib fat emulsion and preparation method thereof |
| CN105748469A (en) * | 2016-02-24 | 2016-07-13 | 长沙佰顺生物科技有限公司 | Anacetrapib and simvastatin medicine composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102008483A (en) | Candesartan-containing compound preparation for treating hypertension | |
| CN105748469A (en) | Anacetrapib and simvastatin medicine composition | |
| CN102008710B (en) | Lisinopril-containing compound preparation for treating hypertension | |
| CN101966187A (en) | Amlodipine- and erbesartan-containing compound preparation for treating hypertension | |
| CN107595851A (en) | A kind of drug compound preparation and the purposes in the medicine for preparing treatment hypertensive patients coronary heart disease | |
| CN107595853A (en) | A kind of medical composition and its use for being used to treat hypertensive patients coronary heart disease | |
| CN1320908C (en) | Granular preparation with pure Chinese medicine for treating hypertension and hyperlipemia and arterial sclerosis | |
| CN101647962A (en) | Traditional Chinese medicine preparation for curing depression | |
| CN107595842A (en) | A kind of drug compound preparation and the purposes in the medicine for preparing treatment hypertensive patients coronary heart disease | |
| CN107595850A (en) | A kind of medical composition and its use for effectively improving sleep quality | |
| CN107693626A (en) | Compound medicine of combination therapy of Chinese and western rhinitis and preparation method thereof | |
| CN105833043A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating primary hypertension | |
| CN105770482A (en) | External composition with sleep improvement function and preparation method thereof | |
| CN105853766A (en) | Purpose of traditional Chinese medicinal preparation for preparing medicine for treating primary hypertension | |
| CN107595849A (en) | A kind of antianxiety and the medical composition and its use for improving sleep | |
| CN107789351A (en) | A kind of Ansai Qu Nilvadipine medical composition and its use | |
| EP3323416A1 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
| CN101966190A (en) | Amlodipine and eprosartan-containing compound preparation for treating hypertension | |
| Maesen et al. | Formoterol suspension aerosol: comparison with formoterol solution aerosol for 12 weeks in asthmatic patients | |
| CN117838800A (en) | Traditional Chinese medicine compound patch for treating recurrent aphtha ulcer and preparation method thereof | |
| CN107737211A (en) | A kind of pharmaceutical composition for treating rhinitis and preparation method thereof | |
| CN107595854A (en) | A kind of combination medicine for treating insomnia | |
| CN107595844A (en) | A kind of Ansai Qu levamlodipine medicinal composition and application thereof | |
| CN102366439A (en) | Self-heated traditional Chinese medicine emplastrum for treating chronic simple rhinitis | |
| CN107670011A (en) | A kind of chinese-western medicine preparation of reducing blood lipid and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180119 |
|
| WW01 | Invention patent application withdrawn after publication |